$heff's $tation of $tocks & $olid DD

[BobaFred]

Not after reading this article....
http://www.fool.com/investing/general/2013/08/24/this-week-in-biotech.aspx

And then there was GTx (NASDAQ: GTXI ) , this week's disaster du jour. GTx shares fell a whopping 65% on the week after a late-stage study of its lead drug enobosarm failed to meet either of its primary endpoints of improving body mass and physical function for non-small cell lung cancer patients. GTx did note an improvement in lean body mass in one of its two trials, but it wasn't enough to meet the primary endpoint of significance in either of its cancer-induced muscle wasting trials. With both of GTx's lead drugs failing to be approved since 2010, GTx's options are quickly running out.